Lipidor Yönetim

Yönetim kriter kontrolleri 2/4

Lipidor CEO'su Ola Holmlund, Sep2018 tarihinde atandı, in görev süresi 6.17 yıldır. şirketin hisselerinin 0.045% doğrudan sahiptir ve bu hisselerin değeri € 3.76K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 15.8 yıl ve 4.8 yıldır.

Anahtar bilgiler

Ola Holmlund

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.2yrs
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	15.8yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Ola Holmlund'un ücretlendirmesi Lipidor'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-SEK 14m
Mar 31 2024	n/a	n/a	-SEK 12m
Dec 31 2023	n/a	n/a	-SEK 11m
Sep 30 2023	n/a	n/a	-SEK 15m
Jun 30 2023	n/a	n/a	-SEK 25m
Mar 31 2023	n/a	n/a	-SEK 30m
Dec 31 2022	n/a	n/a	-SEK 41m
Sep 30 2022	n/a	n/a	-SEK 44m
Jun 30 2022	n/a	n/a	-SEK 28m
Mar 31 2022	n/a	n/a	-SEK 28m
Dec 31 2021	n/a	n/a	-SEK 21m
Sep 30 2021	n/a	n/a	-SEK 15m
Jun 30 2021	n/a	n/a	-SEK 23m
Mar 31 2021	n/a	n/a	-SEK 18m
Dec 31 2020	n/a	n/a	-SEK 16m
Sep 30 2020	n/a	n/a	-SEK 15m
Jun 30 2020	n/a	n/a	-SEK 14m
Mar 31 2020	n/a	n/a	-SEK 14m
Dec 31 2019	n/a	n/a	-SEK 14m
Sep 30 2019	n/a	n/a	-SEK 13m
Jun 30 2019	n/a	n/a	-SEK 10m
Mar 31 2019	n/a	n/a	-SEK 9m
Dec 31 2018	SEK 439k	SEK 300k	-SEK 8m

Tazminat ve Piyasa: Ola şirketinin toplam tazminatının German pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Ola şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Ola Holmlund (55 yo)

6.2yrs

Görev süresi

SEK 439,000

Tazminat

Mr. Ola Holmlund serves as the Chief Executive Officer at Lipidor AB (publ) since September 1, 2018. He served as the Head of Sales at Kibion AB. He has experience in international sales and the launch of...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ola Holmlund	Chief Executive Officer	6.2yrs	SEK 439.00k	0.045% € 3.8k
Olle Holmertz	Founder & Business Controller	15.8yrs	SEK 540.00k	Veri yok
Anders Carlsson	Co-Founder	15.8yrs	SEK 136.00k	Veri yok
Bengt Herslöf	Co-founder & Senior Scientific Advisor	15.8yrs	Veri yok	Veri yok
Jan Holmbäck	Co-Founder & Chief Scientific Officer	15.8yrs	Veri yok	0.11% € 8.7k
Gerhard Miksche	Co-Founder	15.8yrs	Veri yok	Veri yok
Charlotta Ekman	Chief Financial Officer	2.1yrs	Veri yok	Veri yok
Vibhu Rinwa	Chief Operating Officer	less than a year	Veri yok	0.0044% € 364.1

15.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: L7R 'un yönetim ekibi deneyimli ve deneyimlidir ( 15.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gunilla Lundmark	Independent Director	4.8yrs	Veri yok	Veri yok
Ola Flink	Independent Director	7.8yrs	SEK 31.00k	0.059% € 4.9k
Otto Skolling	Independent Director	4.4yrs	Veri yok	Veri yok
Fredrik Sjovall	Independent Chairman of the Board	6.8yrs	SEK 226.00k	0.0049% € 407.2
Denis Angioletti	Independent Director	4.4yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: L7R 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Lipidor Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Lipidor AB (publ), Annual General Meeting, Jun 05, 2024

Insufficient new directors

Lipidor AB (publ), Annual General Meeting, Jun 08, 2023

Lipidor AB (Publ) Appoints Charlotta Ekman as Chief Financial Officer, with Effect from October 1, 2022

Lipidor AB (Publ) Announces Nomination Committee

Recent updates

New major risk - Market cap size

Lipidor AB (publ) Announces First Patient Enrolled in Phase III Study of AKP02G2 for Topical Treatment of Psoriasis

New major risk - Shareholder dilution

Lipidor AB (publ) to Report Fiscal Year 2024 Results on Feb 28, 2025

Lipidor AB (publ) Announces That Clinical Trial Material for Psoriasis Candidate AKP02G2 Has Been Releases According to Plan

First quarter 2024 earnings released: EPS: kr0.011 (vs kr0.014 in 1Q 2023)

Lipidor AB (publ) to Report Fiscal Year 2023 Final Results on May 15, 2024

Lipidor AB (publ) Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2

Full year 2023 earnings released: kr0.40 loss per share (vs kr1.43 loss in FY 2022)

Lipidor Applies to the Indian Medical Products Agency to Start A Phase III study of AKP02G2

Lipidor AB (publ), Annual General Meeting, Jun 05, 2024

Lipidor AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Lipidor AB (publ) Files New Patent Application with the European Patent Office

Second quarter 2023 earnings released: kr0.13 loss per share (vs kr0.30 loss in 2Q 2022)

Insufficient new directors

Lipidor AB (Publ) Confirms Clinical Plan for New Version of Akp02

Full year 2022 earnings released: kr1.43 loss per share (vs kr0.75 loss in FY 2021)

Lipidor AB (publ), Annual General Meeting, Jun 08, 2023

Lipidor AB (publ) to Report Nine Months, 2023 Results on Nov 22, 2023

Lipidor AB (Publ) Provides Update Following Outcome of Phase Iii Study of Psoriasis Candidate Akp02

Lipidor AB (publ) Announces Results from the Its Clinical Phase III Study of AKP02 for Psoriasis

Lipidor Updates on Phase III Clinical Study of Psoriasis Candidate AKP02

Second quarter 2022 earnings released: kr0.30 loss per share (vs kr0.26 loss in 2Q 2021)

Lipidor AB (Publ) Appoints Charlotta Ekman as Chief Financial Officer, with Effect from October 1, 2022

Lipidor AB (Publ) Announces All Patients in Lipidor's Phase III Study with Psoriasis Candidate Akp02 Have Completed Treatment

Lipidor AB (publ) Announces Last Patient Has Been Enrolled in the Ongoing Phase III Study of AKP02 Against Mild to Moderate Psoriasis

Lipidor Ordinary Shares to Be Deleted from OTC Equity

Lipidor Updates on Phase III Study of AKP02 in Treatment of Psoriasis

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis

Lipidor AB (Publ) Expands Clinical Program, Announces Investment in New Drug Development Project Against Acne Vulgaris

No longer forecast to breakeven

Lipidor AB (publ) Announces Approval to Start Phase III Clinical Study of Drug Candidate Akp02 for Treatment of Psoriasis

New 90-day low: €1.04

New 90-day low: €1.17

Cannassure Therapeutics Ltd., Enters into Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based on Lipidor's Akvano Technology

Lipidor AB and Cannassure Therapeutics Ltd Enter Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based on Lipidor's Akvano® Technology

Lipidor AB (publ) to Report Q3, 2021 Results on Nov 17, 2021

Lipidor Signs Cooperation Agreement with Aurena Laboratories AB to Offer Licensees the Opportunity for GMP Production

Lipidor AB (Publ) Announces Nomination Committee

Lipidor AB (publ) to Report Q1, 2021 Results on May 06, 2021

Lipidor Announces Positive Outcome of Feasibility Study for Development of Topical Medical Cannabis Products Based on the Company's Akvano® Technology

First half earnings released

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş